Johnson & Johnson reported strong second-quarter results, surpassing analyst expectations and raising full-year sales and earnings guidance. The company demonstrated solid growth across all segments, particularly in Pharmaceuticals with a 9.7% increase, and management expressed confidence in continued momentum. This positive performance and optimistic outlook are likely to have a positive impact on the stock price in the short term.

[1]